Skip to main content

Table 1 The demographic characteristics and medication use of patients at baseline

From: Do biologic therapies reduce aortic inflammation in rheumatoid arthritis patients?

Clinical characteristics Values
Age (years) 58.4 ± 13.8
Female/male 49/15
Disease duration (years) 13.1 ± 11.8
BMI 21.8 ± 4.0
Smoking, n (%) 8 (12.7)
Hypertension, n (%) 23 (36.5)
Diabetes, n (%) 6 (9.7)
Total cholesterol (mg/dL) 197.4 ± 39.3
LDL (mg/dL) 114.9 ± 37.5
HDL (mg/dL) 59.6 ± 15.0
Triglycerides (mg/dL) 108.2 ± 46.0
PSL use, n (%) 31 (48.4)
PSL dose (mg/day) 2.0 ± 2.3
MTX use, n (%) 45 (70.3)
MTX dose (mg/week) 5.7 ± 3.5
Biologics (IFX/ETN/ADA/GLM/TCZ/ABT) 18/14/16/2/13/1
  1. The data are expressed as the mean ± standard deviation
  2. BMI body mass index; LDL low-density lipoprotein cholesterol; HDL high-density lipoprotein cholesterol; PSL prednisolone; MTX methotrexate; IFX infliximab; ETN etanercept; ADA adalimumab; GLM golimumab; TCZ tocilizumab; ABT abatacept